Abstract:Background: While the reported prevalence of polyneuropathies is 1%-3%, the incidence of hereditary transthyretin amyloidosis in the United States is estimated to be 1 in 100 000 individuals. Polyneuropathies are known to be difficult to treat and lead to significant morbidity. The aim of pain management is symptomatic treatment, with varying approaches to progression prevention being based on the causative pathophysiology.We assessed the prevalence of hereditary amyloid transthyretin variant (ATTRv) amyloidosis, a progressive autosomal dominant multisystem disease caused by the abnormal formation and extracellular deposition of transthyretin protein fibrils in various tissues, in an idiopathic polyneuropathy population by using genetic analysis. Methods: Individuals aged 18 and over with an established diagnosis of polyneuropathy, via electromyography testing that was deemed to be idiopathic, at a large, urban neurology clinic consented to an institutional review board-approved protocol for genetic testing. No further exclusions were made regarding age of onset, family history, axonal neuropathy subtype, comorbidities suggestive of ATTRv amyloidosis, etc. Clinical genetic testing was performed on 134 participants via an 81-gene panel associated with inherited neuromuscular disorders or targeted TTR gene sequencing with deletion and duplication analysis. Results: Within our cohort, 38.06% had at least one reportable finding in one of 38 distinct genes, for a total of 76 reported alterations. Four individuals were identified as having a single pathogenic alteration in an autosomal recessive gene, consistent with carrier status for the 4 following disorders: congenital insensitivity to pain with anhidrosis (NTRK1), Charcot-Marie-Tooth disease type IIP (LRSAM1), Brown-Vialetto-Van Laere syndrome type II (SLC52A2), hereditary sensory and autonomic neuropathy type III (IKBKAP). One individual was found to have a variant of uncertain significance (VUS) (p.G103D) in the TTR gene. Conclusion: Precision medicine on the molecular level with genetic testing in the identification of specific neuropathies may provide clinicians with more detailed information for developing a more direct therapeutic and treatment modality for better-targeted management. Further investigation is needed to expand on the knowledge and understanding of the clinical relevance surrounding the alterations found in the genetic evaluation of idiopathic neuropathy.

Quel est le meilleur biomarqueur électrophysiologique pour le suivi des porteurs asymptomatiques d’une mutation dans le gène de la transthyrétine ?

Identification de biomarqueurs longitudinaux dans les ataxies spinocérébelleuses

Étude prospective des biomarqueurs de marche et d’IRM multimodale chez les patients de la cohorte GAIT’N’PARK présentant une atrophie multisystématisée

Évaluation longitudinale de patients CMT1A sur 1 an : apport de l’IRM neuromusculaire quantifiée

[Analysis of the Pathological Features and Gene Mutations of Chinese Patients with Charcot-Marie-Tooth Disease].

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools

Neuropathies amyloïdes à révélation tardive associées à la mutation Met 30 de la transthyrétine

Quantitative muscle MRI combined with AI‐based segmentation as a follow‐up biomarker for ATTRv patients: A longitudinal pilot study

Real‐life experience with disease‐modifying drugs in hereditary transthyretin amyloid polyneuropathy: A clinical and electrophysiological appraisal

Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations

Management Targeted Genetic Evaluation of an Idiopathic Neuropathy Cohort Through ATTRv Amyloidosis Screening

Axonal excitability as an early biomarker of nerve involvement in hereditary transthyretin amyloidosis

Conséquences diagnostiques de l’étude clinico-génétique de plus de 2000 patients avec suspicion de dégénérescence lobaire frontotemporale

Advanced Echocardiographic Assessment in Transthyretin Amyloidosis: Early Phenotype Markers in Mutation Carriers

Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation

Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009–2019)

Clinical and Biochemical Characterization of Hereditary Transthyretin Amyloidosis Caused by E61K Mutation

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis

Étude moléculaire du polymorphisme de délétion génétique de la Glutathion S-transférase T1 dans les maladies mitochondriales

Late-Onset Familial Amyloid Polyneuropathy With The Ttr Met-30 Mutation In France